Biovie Inc (BIVI)

$1.92 -0.02 (-1.03%)
Market Cap 14.63M
Revenue (ttm) 0.00
Net Income (ttm) -17.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 309,400
Avg Vol 120,468
Day's Range N/A - N/A
Shares Out 7.54M
Stochastic %K 68%
Beta 0.67
Analysts Strong Buy
Price Target $12.00

Company Profile

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 775 888 3162
Address:
680 W. Nye Lane, Suite 204, Carson City, United States
Rod75b15
Rod75b15 Jun. 25 at 1:23 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jun. 25 at 12:02 AM
$BIVI Kong did it!! BiSCAMiuM is the fountain of youth!! # penny scam fraud# split inbound
0 · Reply
Duskfall
Duskfall Jun. 24 at 5:21 PM
$BIVI Lol
0 · Reply
cw6799
cw6799 Jun. 24 at 4:58 PM
$BIVI this shit is toast... jesus
0 · Reply
mshah1615
mshah1615 Jun. 24 at 3:51 PM
$BIVI BIViW looking Good
0 · Reply
joetho
joetho Jun. 23 at 7:55 PM
$BIVI holding
0 · Reply
_2025
_2025 Jun. 23 at 7:55 PM
$BIVI Are You Ready 8$
0 · Reply
TJ12000
TJ12000 Jun. 23 at 5:38 PM
$BIVI snake oil scam company. pay ur lawsuits u POS.
0 · Reply
Sensore
Sensore Jun. 22 at 8:48 PM
$BIVI 🚀
0 · Reply
Tradebait88
Tradebait88 Jun. 22 at 6:50 PM
$BIVI will likely hit on data with that shelf in place
0 · Reply
Latest News on BIVI
BioVie files $300M mixed securities shelf

2026-06-18T21:25:09.000Z - 6 days ago

BioVie files $300M mixed securities shelf

BioVie Registration statement: Registration filing

Jun 18, 2026, 8:00 AM EDT - 7 days ago

BioVie Registration statement: Registration filing

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Jun 5, 2026, 3:31 PM EDT - 19 days ago

Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders?

BioVie Transcript: Investor update

Jun 2, 2026, 4:15 PM EDT - 22 days ago

BioVie Transcript: Investor update

BioVie Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 23 days ago

BioVie Slides: Corporate presentation

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

May 27, 2026, 8:00 AM EDT - 4 weeks ago

Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

2026-05-26T12:32:11.000Z - 4 weeks ago

BioVie announces full enrollment of ADDRESS-LC trial of bezisterim

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

May 26, 2026, 8:00 AM EDT - 4 weeks ago

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

2026-05-18T12:08:40.000Z - 5 weeks ago

BioVie completes SUNRISE-PD trial in early-stage Parkinson’s disease

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

May 18, 2026, 8:00 AM EDT - 5 weeks ago

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease

BioVie Quarterly report: Q3 2026

May 11, 2026, 7:00 AM EDT - 6 weeks ago

BioVie Quarterly report: Q3 2026

BioVie Transcript: KOL event

May 7, 2026, 2:00 PM EDT - 6 weeks ago

BioVie Transcript: KOL event

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

Apr 27, 2026, 8:00 AM EDT - 2 months ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

Apr 16, 2026, 11:30 AM EDT - 2 months ago

BioVie Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

Apr 14, 2026, 8:00 AM EDT - 2 months ago

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

BioVie Slides: Corporate presentation

Apr 1, 2026, 7:00 AM EDT - 3 months ago

BioVie Slides: Corporate presentation

BioVie Transcript: Status update

Mar 4, 2026, 4:15 PM EST - 4 months ago

BioVie Transcript: Status update

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

Feb 12, 2026, 12:12 PM EST - 4 months ago

Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights

BioVie Quarterly report: Q2 2026

Feb 6, 2026, 7:00 AM EST - 4 months ago

BioVie Quarterly report: Q2 2026

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

2026-01-08T13:43:03.000Z - 6 months ago

BioVie completes enrollment in Phase 2 SUNRISE-PD trial

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 24, 2025, 2:05 PM EST - 6 months ago

HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

Nov 19, 2025, 8:00 AM EST - 7 months ago

Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9

BioVie Transcript: AGM 2025

Nov 10, 2025, 2:00 PM EST - 8 months ago

BioVie Transcript: AGM 2025

BioVie Quarterly report: Q1 2026

Nov 10, 2025, 7:00 AM EST - 8 months ago

BioVie Quarterly report: Q1 2026

BioVie Transcript: Investor Update

Oct 8, 2025, 4:15 PM EDT - 9 months ago

BioVie Transcript: Investor Update

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

Sep 26, 2025, 8:00 AM EDT - 9 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

BioVie Proxy statement: Proxy Filing

Sep 25, 2025, 8:00 AM EDT - 9 months ago

BioVie Proxy statement: Proxy Filing

BioVie price target adjusted to $12 from $6 at Brookline

2025-08-29T17:10:18.000Z - 10 months ago

BioVie price target adjusted to $12 from $6 at Brookline

BioVie Annual report: Q4 2025

Aug 15, 2025, 7:00 AM EDT - 11 months ago

BioVie Annual report: Q4 2025

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Aug 13, 2025, 4:05 PM EDT - 11 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

Why Is BioVie Stock (BIVI) Down 50% Today?

2025-08-09T00:43:00.000Z - 11 months ago

Why Is BioVie Stock (BIVI) Down 50% Today?

BioVie 6M share Secondary priced at $2.00

2025-08-08T00:50:12.000Z - 11 months ago

BioVie 6M share Secondary priced at $2.00

BioVie Inc. Announces Pricing of $12 Million Public Offering

Aug 7, 2025, 8:43 PM EDT - 11 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

BioVie Registration statement: Registration Filing

Aug 4, 2025, 8:00 AM EDT - 11 months ago

BioVie Registration statement: Registration Filing

BioVie presents data on Bezisterim at WCAG-2025

2025-07-24T12:20:32.000Z - 1 year ago

BioVie presents data on Bezisterim at WCAG-2025

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

Jul 24, 2025, 8:00 AM EDT - 1 year ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

BioVie appoints Amy Chappell, Kameel Farag to board of directors

2025-07-22T12:11:30.000Z - 1 year ago

BioVie appoints Amy Chappell, Kameel Farag to board of directors

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

BioVie Registration statement: Registration Filing

Jul 22, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Registration statement: Registration Filing

Jul 11, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie reports results from bezisterim Phase 3 NM101 study

2025-07-09T12:22:03.000Z - 1 year ago

BioVie reports results from bezisterim Phase 3 NM101 study

BioVie Inc. trading halted, news pending

2025-07-03T20:50:10.000Z - 1 year ago

BioVie Inc. trading halted, news pending

BioVie Registration statement: Registration Filing

Jul 3, 2025, 8:00 AM EDT - 1 year ago

BioVie Registration statement: Registration Filing

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

2025-06-26T12:16:13.000Z - 1 year ago

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

Jun 26, 2025, 8:00 AM EDT - 1 year ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

Jun 24, 2025, 4:05 PM EDT - 1 year ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

BioVie Transcript: AGM 2025

Jun 23, 2025, 5:00 PM EDT - 1 year ago

BioVie Transcript: AGM 2025

BioVie Proxy statement: Proxy Filing

Jun 2, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Transcript: Status Update

May 28, 2025, 12:00 PM EDT - 1 year ago

BioVie Transcript: Status Update

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-15T12:11:23.000Z - 1 year ago

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

BioVie to host KOL event on Phase 2 study of bezisterim

2025-05-14T11:57:58.000Z - 1 year ago

BioVie to host KOL event on Phase 2 study of bezisterim

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

May 14, 2025, 7:30 AM EDT - 1 year ago

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

BioVie Quarterly report: Q3 2025

May 11, 2025, 6:00 PM EDT - 1 year ago

BioVie Quarterly report: Q3 2025

BioVie Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie to present design of Phase 2 SUNRISE-PD trial

2025-05-07T12:24:31.000Z - 1 year ago

BioVie to present design of Phase 2 SUNRISE-PD trial

BioVie announces formation of Corporate Advisory Board

2025-05-05T12:27:31.000Z - 1 year ago

BioVie announces formation of Corporate Advisory Board

BioVie initiates SUNRISE-PD trial assessing Bezisterim

2025-04-16T12:14:13.000Z - 1 year ago

BioVie initiates SUNRISE-PD trial assessing Bezisterim

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

Mar 27, 2025, 8:00 AM EDT - 1 year ago

BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

BioVie Quarterly report: Q2 2025

Feb 10, 2025, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q2 2025

BioVie Registration statement: Registration Filing

Nov 27, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Registration statement: Registration Filing

Nov 21, 2024, 7:00 AM EST - 1 year ago

BioVie Registration statement: Registration Filing

BioVie Quarterly report: Q1 2025

Nov 12, 2024, 6:00 PM EST - 1 year ago

BioVie Quarterly report: Q1 2025

BioVie Transcript: AGM 2024

Nov 7, 2024, 1:00 PM EST - 1 year ago

BioVie Transcript: AGM 2024

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 4:10 PM EDT - 1 year ago

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Oct 28, 2024, 3:13 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

Oct 24, 2024, 4:10 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 23, 2024, 3:24 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

BioVie Proxy statement: Proxy Filing

Oct 22, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

Oct 15, 2024, 8:00 AM EDT - 1 year ago

BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Oct 11, 2024, 9:00 AM EDT - 1 year ago

BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

GENE

BioVie Annual report: Q4 2024

Sep 29, 2024, 6:00 PM EDT - 1 year ago

BioVie Annual report: Q4 2024

BioVie Proxy statement: Proxy Filing

Sep 27, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Inc. Announces Closing of Public Offering

Sep 25, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Closing of Public Offering

BioVie Inc. Announces Pricing of Public Offering

Sep 23, 2024, 10:26 PM EDT - 1 year ago

BioVie Inc. Announces Pricing of Public Offering

BioVie Inc. Announces Proposed Public Offering

Sep 23, 2024, 4:05 PM EDT - 1 year ago

BioVie Inc. Announces Proposed Public Offering

BioVie Proxy statement: Proxy Filing

Sep 17, 2024, 8:00 AM EDT - 1 year ago

BioVie Proxy statement: Proxy Filing

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 16, 2024, 8:00 AM EDT - 1 year ago

BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

Sep 3, 2024, 8:00 AM EDT - 1 year ago

BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

Aug 27, 2024, 8:45 AM EDT - 1 year ago

BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

Aug 8, 2024, 6:00 AM EDT - 2 years ago

BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease

BioVie Inc. Announces Reverse Stock Split

Aug 6, 2024, 4:40 PM EDT - 2 years ago

BioVie Inc. Announces Reverse Stock Split

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jul 5, 2024, 9:00 AM EDT - 2 years ago

BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

BIAF

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jun 21, 2024, 9:00 AM EDT - 2 years ago

BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

MOB

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Jun 20, 2024, 8:00 AM EDT - 2 years ago

BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

BioVie Proxy statement: Proxy Filing

Jun 17, 2024, 8:00 AM EDT - 2 years ago

BioVie Proxy statement: Proxy Filing

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Jun 12, 2024, 8:24 AM EDT - 2 years ago

Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26

Rod75b15
Rod75b15 Jun. 25 at 1:23 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jun. 25 at 12:02 AM
$BIVI Kong did it!! BiSCAMiuM is the fountain of youth!! # penny scam fraud# split inbound
0 · Reply
Duskfall
Duskfall Jun. 24 at 5:21 PM
$BIVI Lol
0 · Reply
cw6799
cw6799 Jun. 24 at 4:58 PM
$BIVI this shit is toast... jesus
0 · Reply
mshah1615
mshah1615 Jun. 24 at 3:51 PM
$BIVI BIViW looking Good
0 · Reply
joetho
joetho Jun. 23 at 7:55 PM
$BIVI holding
0 · Reply
_2025
_2025 Jun. 23 at 7:55 PM
$BIVI Are You Ready 8$
0 · Reply
TJ12000
TJ12000 Jun. 23 at 5:38 PM
$BIVI snake oil scam company. pay ur lawsuits u POS.
0 · Reply
Sensore
Sensore Jun. 22 at 8:48 PM
$BIVI 🚀
0 · Reply
Tradebait88
Tradebait88 Jun. 22 at 6:50 PM
$BIVI will likely hit on data with that shelf in place
0 · Reply
AshleySchaeffer_BMW
AshleySchaeffer_BMW Jun. 22 at 2:45 PM
$BIVI my 200k warrants here looking nice today...
0 · Reply
emilyparkerr
emilyparkerr Jun. 19 at 7:01 AM
$BIVI nice writeup on the company's mission + pipeline. Bezisterim for Parkinson's & Long COVID, BIV201 for ascites. SUNRISE-PD data due Q3 2026, ADDRESS-LC data due late summer. Two catalysts coming up. https://www.citybiz.co/article/860683/biovie-brings-better-hope-for-a-world-without-debilitating-and-heartbreaking-neurodegenerative-diseases/
0 · Reply
1flaguy
1flaguy Jun. 18 at 9:43 PM
$BIVI $300,000,000 offering prospectus wow holy dilution.... I sold 1/2 buy buy lower if it tanks..
0 · Reply
Thorilium
Thorilium Jun. 18 at 12:40 AM
$CYDY it is not a pill...it's an injection And yes just as with $BIVI it is not excluded that platform drugs can exist for multiple indications
0 · Reply
Rod75b15
Rod75b15 Jun. 17 at 1:54 PM
$BIVI
0 · Reply
Diptheripper_
Diptheripper_ Jun. 17 at 6:13 AM
$BIVI Up up double we go
0 · Reply
Rod75b15
Rod75b15 Jun. 16 at 11:03 AM
$BIVI
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 11 at 3:24 PM
$BIVI
0 · Reply
TJ12000
TJ12000 Jun. 10 at 2:09 PM
$BIVI snake oil gypsy company #deport Kong
0 · Reply
TJ12000
TJ12000 Jun. 8 at 2:46 PM
$BIVI what kind of fake news are these gyps pushing out
0 · Reply
CalculatedSwing
CalculatedSwing Jun. 8 at 1:54 PM
$MX If you're not buying $BIVI right now you're not playing the market right. Cancer news in the next month or so. Its a really good play.
2 · Reply